For the seventh consecutive year, the FDA has renewed Simulations Plus' (SLP) license to the DILIsym software system for facilitating drug safety evaluations.
Simulations Plus, Inc. ( NASDAQ:SLP ) investors will be delighted, with the company turning in some strong numbers with...
Simulations Plus ( NASDAQ:SLP ) Second Quarter 2024 Results Key Financial Results Revenue: US$18.3m (up 16% from 2Q...